Compare NVGS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVGS | PHAR |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United Kingdom | Netherlands |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2013 | 2020 |
| Metric | NVGS | PHAR |
|---|---|---|
| Price | $22.82 | $12.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $21.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 357.7K | 8.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $13.06 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.50 | $8.69 |
| 52 Week High | $23.22 | $21.34 |
| Indicator | NVGS | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 69.68 | 28.24 |
| Support Level | $17.38 | $11.02 |
| Resistance Level | N/A | $17.79 |
| Average True Range (ATR) | 0.70 | 0.36 |
| MACD | 0.15 | -0.47 |
| Stochastic Oscillator | 87.58 | 17.81 |
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.